keyword
MENU ▼
Read by QxMD icon Read
search

infliximab level

keyword
https://www.readbyqxmd.com/read/29660428/the-kinetics-of-anti-drug-antibodies-drug-levels-and-clinical-outcomes-in-infliximab-exposed-patients-with-immuno-mediated-disorders
#1
Nencini Francesca, Vultaggio Alessandra, Pratesi Sara, Cammelli Daniele, Milla Monica, Fiori Ginevra, Bagnoli Siro, Prignano Francesca, Romagnani Sergio, Maggi Enrico, Matucci Andrea
BACKGROUND: Hypersensitivity reactions (HRs) and loss of response (LOR) to infliximab (IFX) are related to drug immunogenicity characterized by anti-drug antibodies (ADA). OBJECTIVE: To analyse the timing of ADA appearance, and its relationship with drug levels and clinical outcomes in IFX-treated patients with different diseases. METHODS: Samples were longitudinally collected before each infusion from 91 IFX-treated patients and were assayed for ADA and drug levels by ELISA and for IgE by CAP-system Clinical data were also monitored, regarding efficacy and safety of therapy...
April 13, 2018: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29659758/accelerated-clearance-of-infliximab-is-associated-with-treatment-failure-in-patients-with-corticosteroid-refractory-acute-ulcerative-colitis
#2
David Kevans, Sanjay Murthy, Diane R Mould, Mark S Silverberg
Background and Aims: A significant proportion of patients with corticosteroid-refractory acute ulcerative colitis [UC] fail therapy. We aimed to assess the pharmacokinetics [PK] of infliximab [IFX] in patients with corticosteroid-refractory acute UC and determine the association between induction IFX PK and short- and long-term therapy outcome. Methods: A population PK model was developed using data from 51 patients with UC [n = 42] and Crohn's disease [n = 9]. A subset of patients [n = 36] with acute corticosteroid-refractory UC (median Mayo score 11 [range 8-12]; 33 of 36 hospitalized; median corticosteroid dose at study entry 50mg prednisolone equivalent IV/oral) commencing IFX were studied to assess further correlations between PK from the first induction dose and therapy outcomes...
April 6, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29623105/subtherapeutic-concentrations-of-infliximab-and-adalimumab-are-associated-with-increased-disease-activity-in-crohn-s-disease
#3
Arne Carlsen, Roald Omdal, Kristian Øgreid Leitao, Kjetil Isaksen, Anne Kristine Hetta, Lars Normann Karlsen, Lars Aabakken, Nils Bolstad, David Warren, Knut E A Lundin, Tore Grimstad
Background: Low anti-tumor necrosis factor α (TNFα) serum concentrations may result in lack of treatment response in patients with inflammatory bowel disease. We determined the anti-TNFα drug concentrations in patients with inflammatory bowel disease and investigated whether or not subtherapeutic drug concentrations were associated with increased levels of disease activity. Methods: In a single-center cross-sectional study, we included patients with ulcerative colitis or Crohn's disease who were receiving infliximab or adalimumab maintenance therapy...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/29608486/simultaneous-quantification-of-adalimumab-and-infliximab-in-human-plasma-by-liquid-chromatography-tandem-mass-spectrometry
#4
Jean-François Jourdil, Benjamin Némoz, Elodie Gautier-Veyret, Charlotte Romero, Françoise Stanke-Labesque
BACKGROUND: Adalimumab (ADA) and infliximab (IFX) are therapeutic monoclonal antibodies (TMabs) targeting tumor necrosis factor-alpha (TNFα). They are used to treat inflammatory diseases. Clinical trials have suggested that therapeutic drug monitoring for ADA or IFX could improve treatment response and cost-effectiveness. However, ADA and IFX were quantified by ELISA in all these studies, and the discrepancies between the results obtained raise questions about their reliability.We describe here the validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of ADA and IFX in human samples...
March 30, 2018: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/29601563/-advances-in-differential-diagnosis-and-treatment-of-patients-with-sarcoidosis
#5
REVIEW
Tadeusz Płusa
The implementation of treatment in patients with sarcoidosis (SA) must be associated with the certainty of diagnosis, which is difficult due to the lack of unambiguous criteria. Finding the presence of noncaseating granulomas in bioptic material is not always indicative of SA. The main point of SA's diagnosis is the level of its activity, because only patients in the active stage should be qualified for treatment. In therapy, glucocorticosteroids or second-line drugs - methotrexate or azathioprine are still recommended...
March 27, 2018: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/29564674/interactions-between-thiopurine-metabolites-adalimumab-and-antibodies-against-adalimumab-in-previously-infliximab-treated-patients-with-inflammatory-bowel-disease
#6
Rikke B Holmstrøm, Ditte V Mogensen, Jørn Brynskov, Mark A Ainsworth, Jacob Nersting, Kjeld Schmiegelow, Casper Steenholdt
BACKGROUND: Interactions between thiopurines and infliximab presumably contribute to superior effect of infliximab-thiopurine combination therapy in patients with inflammatory bowel disease (IBD). We examined whether principal cytotoxic thiopurine metabolites influence adalimumab (ADL) and anti-ADL antibodies (Abs). METHODS: Ninety-eight IBD patients previously treated with infliximab (96%) in whom trough ADL and anti-ADL Abs had been assessed as part of their clinical care were included...
March 21, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29563546/preclinical-development-of-a-novel-orally-administered-anti-tumour-necrosis-factor-domain-antibody-for-the-treatment-of-inflammatory-bowel-disease
#7
J Scott Crowe, Kevin J Roberts, Timothy M Carlton, Luana Maggiore, Marion F Cubitt, Simon Clare, Katherine Harcourt, Jill Reckless, Thomas T MacDonald, Keith P Ray, Anna Vossenkämper, Michael R West
TNFα is an important cytokine in inflammatory bowel disease. V565 is a novel anti-TNFα domain antibody developed for oral administration in IBD patients, derived from a llama domain antibody and engineered to enhance intestinal protease resistance. V565 activity was evaluated in TNFα-TNFα receptor-binding ELISAs as well as TNFα responsive cellular assays and demonstrated neutralisation of both soluble and membrane TNFα with potencies similar to those of adalimumab. Although sensitive to pepsin, V565 retained activity after lengthy incubations with trypsin, chymotrypsin, and pancreatin, as well as mouse small intestinal and human ileal and faecal supernatants...
March 21, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29562373/efficacy-of-switching-to-infliximab-in-patients-with-crohn-s-disease-with-loss-of-response-to-adalimumab
#8
H Peeters, E Louis, F Baert, O Dewit, J C Coche, M Ferrante, G Lambrecht, A Colard, A Van Gossum, P Bossuyt, T Moreels, B Vander Cruyssen, A Gils, M De Vos
BACKGROUND AND STUDY AIMS: Anti-TNF monoclonal antibodies are a cornerstone in the treatment of Crohn's disease. Prospective data on switching from the subcutaneous and human adalimumab (ADM) to the intravenous and chimeric infliximab (IFX) are scarce. PATIENTS AND METHODS: In this prospective, observational, multicentre cohort study we included 21 patients with loss of response to ADM despite at least 4 consecutive weekly injections. Clinical response (CDAI drop≥70 points) and remission (CDAI≤150) were assessed after switching from ADM to IFX after 10 weeks, 6 and 12 months...
January 2018: Acta Gastro-enterologica Belgica
https://www.readbyqxmd.com/read/29543912/tnf-%C3%AE-blockade-impairs-in-vitro-tuberculous-granuloma-formation-and-down-modulate-th1-th17-and-treg-cytokines
#9
Djalma A Alves da Silva, Marcos V da Silva, Cleyson C Oliveira Barros, Patrícia B Dias Alexandre, Rodolfo P Timóteo, Jonatas S Catarino, Helioswilton Sales-Campos, Juliana R Machado, Denise B R Rodrigues, Carlo J Oliveira, Virmondes Rodrigues
Tuberculosis (TB) is a granulomatous disease that has affected humanity for thousands of years. The production of cytokines, such as IFN-γ and TNF-α, is fundamental in the formation and maintenance of granulomas and in the control of the disease. Recently, the introduction of TNF-α-blocking monoclonal antibodies, such as Infliximab, has brought improvements in the treatment of patients with chronic inflammatory diseases, but this treatment also increases the risk of reactivation of latent tuberculosis. Our objective was to analyze, in an in vitro model, the influence of Infliximab on the granulomatous reactions and on the production of antigen-specific cytokines (TNF-α, IFN-γ, IL-12p40, IL-10 and IL-17) from beads sensitized with soluble Bacillus Calmette-Guérin (BCG) antigens cultured in the presence of peripheral blood mononuclear cells (PBMC) from TB patients...
2018: PloS One
https://www.readbyqxmd.com/read/29543362/infliximab-regulates-monocytes-and-regulatory-t-cells-in-kawasaki-disease
#10
Keiichi Koizumi, Minako Hoshiai, Nobuyuki Katsumata, Takako Toda, Hiroaki Kise, Yohei Hasebe, Yosuke Kono, Yuto Sunaga, Masashi Yoshizawa, Atsushi Watanabe, Keiko Kagami, Masako Abe, Kanji Sugita
BACKGROUND: The effect of infliximab (IFX) on immune cells has not been fully reported in Kawasaki disease (KD). To investigate the mechanism of IFX in KD, we examined changes in the abundance of CD14+ CD16+ activated monocytes, regulatory T cells (Treg ), and T-helper cell type 17 (Th17) cells following treatment with IFX. METHODS: We collected peripheral blood from patients with intravenous immunoglobulin (IVIG)-resistant KD and analyzed the absolute counts of CD14+ CD16+ monocytes, Treg cells (CD4+ CD25+ FOXP3+ ) and Th17 cells (CD4+ IL-17A+ ) by flow cytometry...
March 15, 2018: Pediatrics International: Official Journal of the Japan Pediatric Society
https://www.readbyqxmd.com/read/29531640/blood-glucose-changes-surrounding-initiation-of-tumor-necrosis-factor-inhibitors-and-conventional-disease-modifying-anti-rheumatic-drugs-in-veterans-with-rheumatoid-arthritis
#11
Patrick R Wood, Evan Manning, Joshua F Baker, Bryant England, Lisa Davis, Grant W Cannon, Ted R Mikuls, Liron Caplan
AIM: To determine the scope of acute hypoglycemic effects for certain anti-rheumatic medications in a large retrospective observational study. METHODS: Patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry were selected who, during follow-up, initiated treatment with tumor necrosis factor inhibitors (TNFi's, including etanercept, adalimumab, infliximab, golimumab, or certolizumab), prednisone, or conventional disease-modifying anti-rheumatic drugs (DMARDs), and for whom proximate random blood glucose (RBG) measurements were available within a window 2-wk prior to, and 6 mo following, medication initiation...
February 15, 2018: World Journal of Diabetes
https://www.readbyqxmd.com/read/29518978/structural-biology-of-the-tnf%C3%AE-antagonists-used-in-the-treatment-of-rheumatoid-arthritis
#12
REVIEW
Heejin Lim, Sang Hyung Lee, Hyun Tae Lee, Jee Un Lee, Ji Young Son, Woori Shin, Yong-Seok Heo
The binding of the tumor necrosis factor α (TNFα) to its cognate receptor initiates many immune and inflammatory processes. The drugs, etanercept (Enbrel® ), infliximab (Remicade® ), adalimumab (Humira® ), certolizumab-pegol (Cimzia® ), and golimumab (Simponi® ), are anti-TNFα agents. These drugs block TNFα from interacting with its receptors and have enabled the development of breakthrough therapies for the treatment of several autoimmune inflammatory diseases, including rheumatoid arthritis, Crohn's disease, and psoriatic arthritis...
March 7, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29496351/efficacy-and-safety-of-infliximab-biosimilar-inflectra-%C3%A2-in-severe-sarcoidosis
#13
Milou C Schimmelpennink, Adriane D M Vorselaars, Frouke T van Beek, Heleen A Crommelin, Vera H M Deneer, Ruth G M Keijsers, Marcel Veltkamp
BACKGROUND: Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy in severe sarcoidosis. The originator product of Infliximab, Remicade® , is expensive, limiting universal access. Recently, a less expensive biosimilar of infliximab, Inflectra® , has become available, but the efficacy and tolerability has not been studied in sarcoidosis. METHODS: In this retrospective cohort study, 29 patients treated with the infliximab biosimilar Inflectra® , were analysed...
February 19, 2018: Respiratory Medicine
https://www.readbyqxmd.com/read/29481661/early-response-to-therapy-predicts-6-month-and-1-year-disease-activity-outcomes-in-psoriatic-arthritis-patients
#14
Monika M Schoels, Uriel Landesmann, Farideh Alasti, Daniel Baker, Josef S Smolen, Daniel Aletaha
Objectives: In PsA management, remission and low disease activity represent preferential treatment targets. We aimed at evaluating the predictive value and clinical use of initial therapeutic response for subsequent achievement of these targets. Methods: Based on data of 216 patients enrolled in a randomized controlled trial of golimumab (GO-REVEAL), we performed diagnostic testing analyses using 3- and 6-month disease activity as tests for treatment outcomes to understand the implications of early response...
February 22, 2018: Rheumatology
https://www.readbyqxmd.com/read/29474531/subtherapeutic-infliximab-trough-levels-and-complete-mucosal-healing-are-associated-with-sustained-clinical-remission-after-infliximab-cessation-in-paediatric-onset-crohn-s-disease-patients-treated-with-combined-immunosuppressive-therapy
#15
Ben Kang, So Yoon Choi, Young Ok Choi, Min-Ji Kim, Kyunga Kim, Ji-Hyuk Lee, Yon Ho Choe
Background and aims: We aimed to investigate the outcome in paediatric-onset Crohn's disease patients who had discontinued infliximab after maintaining clinical remission with combined immunosuppression, and to determine factors associated with clinical relapse. Methods: We conducted a retrospective observational study of 63 paediatric-onset Crohn's disease patients who had stopped scheduled infliximab during sustained corticosteroid-free clinical remission for at least 1 year with infliximab and azathioprine, and were followed up for at least 1 year thereafter...
February 21, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29464314/activation-status-of-peripheral-blood-neutrophils-and-the-complement-system-in-adult-rheumatoid-arthritis-patients-undergoing-combined-therapy-with-infliximab-and-methotrexate
#16
Larissa F Marchi, Adriana B Paoliello-Paschoalato, Renê D R Oliveira, Ana Elisa C S Azzolini, Luciana M Kabeya, Eduardo A Donadi, Yara Maria Lucisano-Valim
We examined the functional activity of peripheral blood neutrophils and the complement system activation status in patients with rheumatoid arthritis (RA) undergoing infliximab/methotrexate combined therapy. We studied female RA patients under treatment with infliximab (3-5 mg/kg) and methotrexate (15-25 mg/week) who presented inactive (i-RA; n = 34, DAS-28 ≤ 2.6) or at least moderately active disease (a-RA; n = 29, DAS-28 > 3.2), and age-matched healthy women (n = 38). We measured the levels of reactive oxygen species (ROS) generation (chemiluminescence assay) and membrane expression of FcγRIIa/CD32, FcγRIIIb/CD16, CR1/CD35, and CR3/CD11b receptors (ELISA assay) in neutrophils...
February 20, 2018: Rheumatology International
https://www.readbyqxmd.com/read/29462398/full-interchangeability-in-regard-to-immunogenicity-between-the-infliximab-reference-biologic-and-biosimilars-ct-p13-and-sb2-in-inflammatory-bowel-disease
#17
Gionata Fiorino, M Begoña Ruiz-Argüello, Ainara Maguregui, Daniel Nagore, Carmen Correale, Simona Radice, Daniela Gilardi, Mariangela Allocca, Federica Furfaro, Antonio Martínez, Silvio Danese
Background: Infliximab (IFX) biosimilars CT-P13 and SB2 have comparable efficacy, safety, and immunogenicity to the originator Remicade (RMC). However, concerns about cross-switching patients between the 3 brands were raised in the absence of cross reactivity data between them. We aimed to determine whether antibodies to infliximab (ATI) in inflammatory bowel disease (IBD) patients cross-react with RMC, CT-P13, and SB2. Methods: Based on previous ATI status, samples from 34 patients participating in the BIOSIM01 study (13 RMC, 9 CT-P13, and 12 switchers) were selected...
February 15, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29458298/%C3%AE-amyloid-inhibits-hippocampal-ltp-through-tnfr-ikk-nf-%C3%AE%C2%BAb-pathway
#18
Manikandan Samidurai, Vijay S Ramasamy, Jihoon Jo
Objective The suppressive action of the acute application of oligomeric amyloid-β (Aβ) on hippocampal long-term potentiation (LTP) has been reported widely. Many mechanisms have been proposed for Aβ inhibited LTP induction. The inflammatory cytokine tumor necrosis factor-α (TNF-α) has also been reported to play a key role in this LTP inhibition through Aβ. However, the underlying molecular mechanisms are largely unknown. This study aimed to investigate the link between Aβ- and TNF-α-mediated hippocampal LTP inhibition...
February 20, 2018: Neurological Research
https://www.readbyqxmd.com/read/29446129/editorial-infliximab-trough-levels-and-histological-healing-in-ulcerative-colitis-a-step-towards-personalised-biologic-therapy
#19
EDITORIAL
T Lobaton, M De Vos
No abstract text is available yet for this article.
March 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29446128/editorial-restoring-therapeutic-infliximab-drug-levels-in-patients-with-loss-of-response-pharmacokinetics-and-anti-drug-antibodies-as-useful-guidance-tools
#20
EDITORIAL
S Ben-Horin
No abstract text is available yet for this article.
March 2018: Alimentary Pharmacology & Therapeutics
keyword
keyword
53792
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"